1160395-86-7

Basic information

• Product Name: N-[3-(1-piperidinyl)propyl]-2-{[4-(4-pyridinyl)phenyl]carbonyl}hydrazinecarbothioamide
• Synonyms: N-[3-(1-piperidinyl)propyl]-2-{[4-(4-pyridinyl)phenyl]carbonyl}hydrazinecarbothioamide
• CAS NO: 1160395-86-7
• Molecular Weight: 397.544
• Mol File: 1160395-86-7.mol

Chemical Properties

• CAS DataBase Reference: N-[3-(1-piperidinyl)propyl]-2-{[4-(4-pyridinyl)phenyl]carbonyl}hydrazinecarbothioamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[3-(1-piperidinyl)propyl]-2-{[4-(4-pyridinyl)phenyl]carbonyl}hydrazinecarbothioamide(1160395-86-7)
• EPA Substance Registry System: N-[3-(1-piperidinyl)propyl]-2-{[4-(4-pyridinyl)phenyl]carbonyl}hydrazinecarbothioamide(1160395-86-7)

Safety Data

• Hazardous Substances Data: 1160395-86-7(Hazardous Substances Data)

Upstream product

• 32813-23-3 1-(3-isothiocyanato-propyl)-piperidine 
• 619328-60-8 4-(pyridin-4-yl)benzohydrazide 

Downstream Products

• 1160395-60-7 N-[3-(1-piperidinyl)propyl]-5-[4-(4-pyridinyl)phenyl]-1,3,4-oxadiazol-2-amine 

Relevant articles and documents

5-ARYL-1,3,4-OXADIAZOLE-2-AMINES AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS

The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, compositions containing them and their use in the treatment of neurological, psychiatric disorders and gastrointestinal disorders. wherein R1 and R2 independently represent hydrogen, C1-6 alkyl or C3-6 cycloalkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a nitroge containing heterocyclyl group which is unsubstituted or substituted with 1, 2, or 3 substituents selected from methyl or fluoro; Q represents -(CH2)n- wherein n represents 3 or 4; A represents a phenyl ring and B represents a 5 or 6 membered heteroaryl ring or B represents a phenyl ring and A represents a 5 or 6 membered heteroaryl ring; R3 and R4 independently represent C1-6 alkyl, C1-6 alkoxy and halo; t and m independently represent an integer from 0 to 3. Compounds of formula (I) and their pharmaceutically acceptable salts may have affinity for and be agonists at the nicotinic α7 receptor and are believed to be of potential use in the treatment of neurological diseases including Alzheimer's disease.